A healthy 30-year-old woman has only about a 20% chance each month to get pregnant naturally. Worldwide 1 in 6 couples experience infertility problems at least once during their reproductive life. In vitro fertilization (IVF) success rates are similar, with only around 30% cycles resulting in a healthy pregnancy. The leading cause of in vitro fertilization (IVF) failure is the transfer of embryos with an abnormal number of chromosomes. Chromosomal abnormalities in the embryo may lead to embryo development arrest, failed implantation or miscarriage during pregnancy.Preimplantation genetic screening at INVICTA enables the selection of embryos with a normal number of chromosomes helping to improve your chances for a successful outcome of IVF treatment.
The success of IVF is heavily influenced by maternal age and the couple’s reproductive history. IVF success rates begin to fall dramatically with increasing of the maternal age reaching around 32% for women under 35 and less than 10% for women aged 40-44. Advanced maternal age (AMA) or repeated IVF failure may indicate that the infertility is caused by the production of aneuploid gametes. Recent studies suggest that over 50% of embryos are aneuploid what could explain most implantation failures and miscarriages.
PGS testing is performed as part of an IVF cycle with the goal of improving the chance of becoming pregnant and lowering the risk of miscarriage after embryo transfer. PGS tests for the number of chromosome make it possible to select embryos with the normal number of chromosomes (46) that have a better chance of implanting and resulting in a healthy pregnancy.
Since 1993 when Munne et all., developed protocols for multicolor-FISH to screen up to five chromosomes simultaneously, PGS is has been undergoing continuous evolution especially when it comes to the technology used: from fluorescence in-situ hybridization (FISH) to array comparative genomic hybridization (aCGH), and recently to next generation sequencing (NGS). The initial “PGS1” (FISH based) was shown to be ineffective in improving in vitro fertilization (IVF) pregnancy rates and in reducing miscarriage rates. In comparison with “PGS1”, the improved approach of “PGS2” where fluorescence in-situ hybridization (FISH) is replaced by techniques that allows more accurate diagnosis of aneuploidy of all 24 chromosome pairs (aCGH, NGS), was shown to increases IVF success. Because of the further advantage of superior sensitivity and specificity and therefore the best outcomes benefits for IFV, NGS method for PGS is now being promoted.
Experts from INVICTA laboratory developed preimplantation genetic screening test of all 24 chromosomes (PGS) to increase your IVF success. The PGS NGS 360°™ technology delivers aneuploidy screening of embryos before transfer, so that only euploid embryos are transferred. Outcomes that can be measured to estimate our IVF success rate include: implantation rate (IR), biochemical pregnancy rate (BPR), clinical pregnancy rate (CPR), miscarriage rates (MR).
During last two years INVICTA Laboratory performed 106 embryo transfers together with PGS for aneuploidy using NGS. By comparing the results with the group of IVF patients without PGS, we show that our PGS-NGS 360°™ Chromosome screening gives us marked improvements in pregnancy and implantation rates. The BPR per embryo transfer was 49%. The clinical PR (defined as detection of an ultrasound fetal heartbeat at 6 weeks and 1–3 days) was 46,2%. An increase was also found in implantation rate that reached 40,5%. By increasing patients chance for successful IVF our PGS-NGS 360°™ Chromosome screening can save the expensive cost of further cycles of treatment and what is the most makes the whole IVF procedure less stressful for patients and shortens the time they have to await to enjoy their offspring.